PNC-27 10mg
PNC-27 is a research-grade peptide that has gained attention for its potential benefits in cancer research, particularly in its role as an anti-cancer agent. This peptide is intended for laboratory and preclinical research applications.
Key Features
- Research-grade peptide (99+% purity, third-party tested)
- Investigated for in medical oncology for potential anti-cancer properties
- Lyophilized for investigator-controlled reconstitution and dosing
- Available format: 10 mg total
Product Specifications
- Product Name: PNC-27 10mg (Purity: >99+% HPLC)
- Category: Anti-cancer peptide (research chemical)
- Supplied in: Lyophilized powder in sterile vial + 3 mL bacteriostatic water
- Administration (research/preclinical): Subcutaneous injection preferred
- Storage (reconstituted): Refrigerate at 2–8 °C; use within 30 days; avoid freeze-thaw cycles
Mechanism of Action
PNC-27 is an experimental anti-cancer peptide. Its primary function and reported benefits in early research include:
- Selective Cancer Cell Destruction: It binds to the HDM-2 protein located on the membranes of cancer cells, which forms pores and causes the cancer cell to rupture and die (necrosis).
- Safety for Healthy Cells: In laboratory studies, PNC-27 selectively targets and kills cancer cells while leaving normal, untransformed cells unharmed.
- Broad Efficacy: Research indicates it is cytotoxic to a variety of cancer types, including breast, pancreatic, cervical, and melanoma, as well as multiple myeloma.
- Synergy with Metabolic Therapy: Some recent studies suggest that combining PNC-27 with ketone bodies (like lithium acetoacetate) can significantly enhance the peptide's effectiveness at lower doses.
- Potential for Decreased Tumor Viability: Preliminary studies indicate that PNC-27 may inhibit tumor growth and enhance the efficacy of existing cancer treatments, making it an exciting candidate for further research in oncology.
Dosing Guide
PNC-27 is typically administered via subcutaneous injection. The recommended dosing regimen is as follows:
- Initial Dose: For most research applications, the initial dose typically ranges from 0.5 to 2.0 mg, which translates to:
- 5 to 20 units on a U-100 insulin syringe (considering 1 mg = 10 units for a 10 mg/mL solution).
- Maximum Dose: Do not exceed a recommended dose of 3.0 mg, which equals:
- 30 units on a U-100 insulin syringe.
- Frequency of Administration: PNC-27 can be administered up to once daily, based on individual tolerance and response, but should not be used more frequently than every 48 hours to assess effectiveness and avoid potential side effects.
Reconstitution Protocol (10mg Vial)
For optimal reconstitution, it is recommended to use bacteriostatic water.
- Prep: Wipe the vial stoppers of both the PNC-27 and the bacteriostatic water with alcohol swabs.
- Draw: Using a 1 mL or 3 mL syringe, draw 1.0 mL of bacteriostatic water.
- Inject: Slowly inject the bacteriostatic water into the peptide vial, directing the stream to the side of the vial to avoid damaging the peptide structure.
- Dissolve: Gently swirl the vial between your fingers. Do not shake. The solution should be clear.
- Storage: Store reconstituted vials in a refrigerator at 2°C–8°C (39°F).
This results in a concentration of 10 mg/mL (assuming a 10 mg vial reconstituted with 1 mL BAC water).
Safety Information
- Side Effects: Common side effects may include injection site reactions, nausea, and transient headaches.
- Contraindications: Not recommended for individuals with uncontrolled hypertension or a history of cancer.
- Health Warnings: Use caution in individuals with pre-existing medical conditions, and consult with a healthcare professional before starting any new peptide regimen.
Legal and Regulatory Notice
By purchasing this product, you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical standards, and customs requirements. Liability for misuse is disclaimed.
